Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AUPH Aurinia Pharmaceuticals

Not Yet Opened 01-16 16:00:00 EST

14.85

-0.02

-0.13%

盘后14.45

-0.40-2.69%

19:16 EST

High15.08	Low14.78	Vol1.22M
Open14.78	D1 Closing14.87	Amplitude2.02%
Mkt Cap1.96B	Tradable Cap1.90B	Total Shares131.84M
T/O18.10M	T/O Rate0.95%	Tradable Shares128.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals","latestPrice":14.85,"timestamp":1768597200000,"preClose":14.87,"halted":0,"volume":1215350,"hourTrading":{"tag":"盘后","latestPrice":14.45,"preClose":14.85,"latestTime":"19:16 EST","volume":456167,"amount":6747901.9062,"timestamp":1768609003473,"change":-0.4,"changeRate":-0.026936,"amplitude":0},"delay":0,"changeRate":-0.001344989912575627,"floatShares":128060726,"shares":131840559,"eps":0.5501,"marketStatus":"Not Yet Opened","change":-0.02,"latestTime":"01-16 16:00:00 EST","open":14.78,"high":15.08,"low":14.78,"amount":18098389.3864,"amplitude":0.020175,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.5501,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":14.87,"preHourTrading":{"tag":"盘前","latestPrice":14.97,"preClose":14.87,"latestTime":"09:04 EST","volume":100,"amount":1474.7,"timestamp":1768572297000,"change":0.1,"changeRate":0.006725,"amplitude":0.046402},"postHourTrading":{"tag":"盘后","latestPrice":14.45,"preClose":14.85,"latestTime":"19:16 EST","volume":456167,"amount":6747901.9062,"timestamp":1768609003473,"change":-0.4,"changeRate":-0.026936,"amplitude":0},"volumeRatio":1.137956657271241,"impliedVol":0.6109,"impliedVolPercentile":0.7769},"requestUrl":"/m/hq/s/AUPH/wiki","defaultTab":"wiki","newsList":[{"id":"2600682630","title":"Saturn Oil & Gas Completes Amalgamation with Subsidiaries","url":"https://stock-news.laohu8.com/highlight/detail?id=2600682630","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600682630?lang=en_us&edition=fundamental","pubTime":"2026-01-02 20:01","pubTimestamp":1767355292,"startTime":"0","endTime":"0","summary":"Saturn Oil & Gas Inc. has announced the completion of a corporate reorganization through a vertical short-form amalgamation with its two wholly-owned subsidiaries, 1777241 Alberta Ltd.  and Clearview Resources Ltd., effective January 1, 2026. This move consolidates Saturn’s asset base and development activities under a single corporate entity, aiming to reduce corporate and operational expenses. The company stated that no action is required from existing shareholders and that share certificates remain unaffected. The certificate of amalgamation is available on Saturn's SEDAR+ profile.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saturn Oil & Gas Inc. published the original content used to generate this news brief via Newsfile  on Jan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDLzp474:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2591681397","title":"STEP Energy Services Ltd. Held Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2591681397","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591681397?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:15","pubTimestamp":1765574123,"startTime":"0","endTime":"0","summary":"STEP Energy Services Ltd. held a special meeting of shareholders, where approval was given for an arrangement involving ARC Energy Fund 8 and 2659160 Alberta Ltd. Under this arrangement, these parties will acquire all issued and outstanding common shares of STEP Energy Services Ltd., except those already owned or controlled by ARC-related entities, for $5.50 in cash per share. The arrangement received shareholder approval at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STEP Energy Services Ltd. published the original content used to generate this news brief via Business Wire  on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL3Q91qy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2588202905","title":"Aurinia Pharmaceuticals Shares Fall After Leerink Partners Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2588202905","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588202905?lang=en_us&edition=fundamental","pubTime":"2025-12-04 04:36","pubTimestamp":1764794183,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  shares fell 6.6% in recent Wednesday trading after Leerink Partners downgraded the stock to market perform from outperform and increased its price target to $16 from $15.Intraday volume topped 2.22 million shares, versus the daily average of 1.77 million.Price: 14.86, Change: -1.05, Percent Change: -6.60","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUPH"],"gpt_icon":0},{"id":"2588041960","title":"Aurinia Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041960","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041960?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:43","pubTimestamp":1764769380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AUPH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 08:43 ET (13:43 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2588868043","title":"Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $16 From $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2588868043","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588868043?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:40","pubTimestamp":1764762041,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has an average rating of overweight and mean price target of $16.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PT","AUPH"],"gpt_icon":0},{"id":"2588048341","title":"Aurinia Pharmaceuticals Inc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $16 From $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2588048341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588048341?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:14","pubTimestamp":1764760487,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X9087:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2586220603","title":"A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation Following Recent Share Price Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2586220603","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586220603?lang=en_us&edition=fundamental","pubTime":"2025-11-28 03:22","pubTimestamp":1764271326,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) shares have been steadily gaining ground this month. This trend reflects investor optimism around the company’s performance in the autoimmune therapeutics space. Recent trading shows a positive momentum for the stock.\nSee our latest analysis for Aurinia Pharmaceuticals.\nAurinia Pharmaceuticals' 1-month share price return of 33.2% is part of an even stronger year-to-date rally, with shares climbing 86.66%. The stock’s 1-year total shareholder return stands at...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/a-look-at-aurinia-pharmaceuticals-nasdaqgmauph-valuation-fol","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/a-look-at-aurinia-pharmaceuticals-nasdaqgmauph-valuation-fol","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2584925998","title":"Aurinia Pharmaceuticals Q3 Operating Income USD 29.745 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584925998","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584925998?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:30","pubTimestamp":1763569830,"startTime":"0","endTime":"0","summary":"Nov 04 (Reuters) - Aurinia Pharmaceuticals Q3 product revenue USD 70.627 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 04-NOV-202510:55:11.793 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2C81Cy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"1128418193","title":"Stock Track | Aurinia Pharmaceuticals Soars 5.04% Following Strong Q3 Results and Raised 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1128418193","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128418193?lang=en_us&edition=fundamental","pubTime":"2025-11-12 03:02","pubTimestamp":1762887765,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) saw its stock soar 5.04% in intraday trading on Tuesday, following the company's impressive third-quarter results and an optimistic outlook for 2025. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUPH"],"gpt_icon":0},{"id":"2582360230","title":"Aurinia Pharmaceuticals (NasdaqGM:AUPH): Valuation Insights Following Strong Q3 Results and Raised 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2582360230","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582360230?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:30","pubTimestamp":1762871436,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) just delivered a strong show for investors with better-than-expected third quarter results and an updated outlook for 2025. The company raised both its revenue and net product sales guidance, which suggests growing confidence in its business trajectory.\nSee our latest analysis for Aurinia Pharmaceuticals.\nAurinia Pharmaceuticals’ strong financial report and higher guidance have clearly energized the stock, with a 13% seven-day share price return and an...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-nasdaqgmauph-valuation-insights-foll","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-nasdaqgmauph-valuation-insights-foll","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AUPH","BK4139","DCF"],"gpt_icon":0},{"id":"2581839558","title":"Aurinia Pharmaceuticals Shares Rise After Jefferies Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2581839558","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581839558?lang=en_us&edition=fundamental","pubTime":"2025-11-08 04:17","pubTimestamp":1762546672,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  shares were up 4.4% in recent Friday trading after Jefferies upgraded the stock to buy from hold and adjusted its price target to $21 from $10.Trading volume stood at over 1.9 million shares, versus the daily average of about 1.8 million.Price: 14.56, Change: +0.61, Percent Change: +4.37","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUPH"],"gpt_icon":0},{"id":"1141642479","title":"Stock Track | Aurinia Pharmaceuticals Soars 9.23% Pre-Market on Jefferies Upgrade and Doubled Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1141642479","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141642479?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:50","pubTimestamp":1762527020,"startTime":"0","endTime":"0","summary":"Shares of Aurinia Pharmaceuticals (AUPH) are soaring 9.23% in pre-market trading on Friday, following a significant upgrade from Jefferies. The investment bank raised its rating on the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUPH"],"gpt_icon":0},{"id":"2581800700","title":"Aurinia Pharmaceuticals Raised to Buy From Hold by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2581800700","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581800700?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:21","pubTimestamp":1762518060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AUPH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 07:21 ET (12:21 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2581057420","title":"Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2581057420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581057420?lang=en_us&edition=fundamental","pubTime":"2025-11-07 18:15","pubTimestamp":1762510539,"startTime":"0","endTime":"0","summary":"Jefferies upgraded Aurinia Pharmaceuticals (AUPH) to Buy from Hold with a price target of $21, up from $10. The company’s commercial performance wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aurinia-pharmaceuticals-upgraded-to-buy-from-hold-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aurinia-pharmaceuticals-upgraded-to-buy-from-hold-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0},{"id":"2581092514","title":"Bloom Burton downgrades Aurinia Pharmaceuticals (AUPH) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2581092514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581092514?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:57","pubTimestamp":1762441047,"startTime":"0","endTime":"0","summary":"Bloom Burton analyst David Martin PhD downgraded Aurinia Pharmaceuticals to a Hold yesterday and set a price target of $13.00. According to TipRank...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bloom-burton-downgrades-aurinia-pharmaceuticals-auph-to-a-hold-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bloom-burton-downgrades-aurinia-pharmaceuticals-auph-to-a-hold-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0},{"id":"1134482445","title":"Stock Track | Aurinia Pharmaceuticals Plummets 5.05% Following RBC Downgrade to Sector Perform","url":"https://stock-news.laohu8.com/highlight/detail?id=1134482445","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134482445?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:09","pubTimestamp":1762355352,"startTime":"0","endTime":"0","summary":"Shares of Aurinia Pharmaceuticals (AUPH) plunged 5.05% in pre-market trading on Wednesday following a downgrade by RBC Capital Markets. The Canadian multinational bank revised its rating on the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUPH"],"gpt_icon":0},{"id":"2581727814","title":"Aurinia Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581727814","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581727814?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:46","pubTimestamp":1762346760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AUPH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 07:46 ET (12:46 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2581724604","title":"RBC Downgrades Aurinia Pharmaceuticals to Sector Perform From Outperform, Raises Price Target to $15 From $9, Keeps Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724604","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724604?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:19","pubTimestamp":1762345147,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has an average rating of overweight and mean price target of $14.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUPH"],"gpt_icon":0},{"id":"2581072641","title":"H.C. Wainwright Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581072641","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581072641?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:37","pubTimestamp":1762342641,"startTime":"0","endTime":"0","summary":"In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $17.00. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-aurinia-pharmaceuticals-auph-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-aurinia-pharmaceuticals-auph-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0},{"id":"2581073767","title":"Aurinia Pharmaceuticals (AUPH) was downgraded to a Hold Rating at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581073767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581073767?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:55","pubTimestamp":1762293320,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Miehm from RBC Capital downgraded Aurinia Pharmaceuticals to a Hold, with a price target of $15.00. The company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-auph-was-downgraded-to-a-hold-rating-at-rbc-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-auph-was-downgraded-to-a-hold-rating-at-rbc-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0595},{"period":"3month","weight":0.2857},{"period":"6month","weight":0.7207},{"period":"1year","weight":0.9186},{"period":"ytd","weight":-0.069}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.073364},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00852},{"month":3,"riseRate":0.454545,"avgChangeRate":0.093863},{"month":4,"riseRate":0.636364,"avgChangeRate":-0.008728},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.008134},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.02016},{"month":7,"riseRate":0.636364,"avgChangeRate":0.041551},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014541},{"month":9,"riseRate":0.454545,"avgChangeRate":0.063835},{"month":10,"riseRate":0.583333,"avgChangeRate":0.048963},{"month":11,"riseRate":0.583333,"avgChangeRate":0.036405},{"month":12,"riseRate":0.416667,"avgChangeRate":0.092842}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aurinia Pharmaceuticals,AUPH,Aurinia Pharmaceuticals股票,Aurinia Pharmaceuticals股票老虎,Aurinia Pharmaceuticals股票老虎国际,Aurinia Pharmaceuticals行情,Aurinia Pharmaceuticals股票行情,Aurinia Pharmaceuticals股价,Aurinia Pharmaceuticals股市,Aurinia Pharmaceuticals股票价格,Aurinia Pharmaceuticals股票交易,Aurinia Pharmaceuticals股票购买,Aurinia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}